Conduit Pharmaceuticals Inc. (CDT)
NASDAQ: CDT · Real-Time Price · USD
1.820
+0.080 (4.60%)
At close: Aug 13, 2025, 4:00 PM
1.800
-0.020 (-1.10%)
Pre-market: Aug 14, 2025, 9:03 AM EDT
Company Description
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility.
Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products.
The company was founded in 2019 and is based in Naples, Florida.
Conduit Pharmaceuticals Inc.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Andrew Regan |
Contact Details
Address: 4581 Tamiami Trail North, Suite 200 Naples, Florida 34103 United States | |
| Phone | (646)-491-9132 |
| Website | conduitpharma.com |
Stock Details
| Ticker Symbol | CDT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001896212 |
| CUSIP Number | 20678X106 |
| ISIN Number | US20678X1063 |
| Employer ID | 87-3272543 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Andrew Regan | Founder, Chief Executive Officer and Director |
| James Bligh | Interim Chief Financial Officer and Director |
| Dr. David Joszef Tapolczay | Head of Strategy and Licensing |
| Dr. Joanne M. Holland | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 12, 2025 | 424B3 | Prospectus |
| Aug 11, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 8, 2025 | 8-K | Current Report |
| Aug 7, 2025 | EFFECT | Notice of Effectiveness |
| Jul 31, 2025 | SCHEDULE 13D/A | Filing |
| Jul 31, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jul 8, 2025 | DEF 14A | Other definitive proxy statements |
| Jul 8, 2025 | ARS | Filing |
| Jun 9, 2025 | 8-K | Current Report |
| Jun 3, 2025 | 8-K | Current Report |